Renalytix Gets FDA De Novo Marketing Authorization for KidneyIntelX.dkd
29 Junio 2023 - 5:58PM
Noticias Dow Jones
By Stephen Nakrosis
Renalytix said the Food and Drug Administration has granted De
Novo marketing authorization for the KidneyIntelX.dkd prognostic
test.
Renalytix said the authorization "affirms KidneyIntelX as a
first-in-class, artificial intelligence enabled prognostic testing
platform to guide care management for adults with type 2 diabetes
and early stage chronic (diabetic) kidney disease."
De Novo authorization provides a marketing pathway for novel
medical devices, the FDA said.
Renalytix also said it believes the authorization will lead to
increasing test adoption, expanding insurance coverage, and the
pursuit of additional international regulatory approvals.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 29, 2023 18:43 ET (22:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Renalytix (NASDAQ:RNLX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Renalytix (NASDAQ:RNLX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
